SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as investors gear up for a pivotal earnings report, with community sentiment largely driven by expectations of an revenue beat and the potential for accelerated infrastructure development. While some participants are closely monitoring the company's ability to convert its massive contract backlog into recurring revenue, others are focused on Wes Cummins' execution timeline, which many believe is years ahead of industry peers.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is experiencing extreme volatility following the release of FDA briefing documents that challenged the statistical validity of the HOPE-3 trial data, leading to investor uncertainty ahead of the upcoming advisory committee meeting. While bearish participants and some analysts point to concerns over clinical trial design and statistical methodology, bulls are rallying behind the company's rebuttal, which argues the FDA relied on an obsolete analysis plan, sparking intense community debate about the legitimacy of the agency's review versus the company's clinical disclosures.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is surging following a strong quarterly report that featured revenue and earnings beats, fueled by sustained, high-growth demand in the AI infrastructure and data center sectors. While some community members debate the sustainability of recent price swings and margin comparisons to other industries, investors remain broadly bullish, citing the company's critical role in hyperscaler expansion and long-term earnings acceleration.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The semiconductor sector, represented by the SMH ETF, is experiencing extreme volatility and a significant rotation of capital as investors weigh AI spending sustainability against historically high trading volumes and mixed institutional signals. While technical indicators show the sector testing critical support levels, the community remains divided between those viewing the recent selloff as a healthy capitulation event and others who fear a broader, fundamental reckoning in AI infrastructure demand.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is facing significant downward pressure as investors rotate out of high-beta AI infrastructure stocks and digest recent legal challenges regarding patent infringement. While some in the community remain focused on the long-term potential of GaN and SiC power technology in AI data centers, others are expressing frustration over management's lack of concrete contract announcements and the impact of recent equity offerings.

Fundrise Innovation Fund LLC operates as a non-diversified, closed-end management investment company. It invests in growing tech companies to help them expand and generate profits. The company was founded on June 7, 2021 and is headquartered in Washington, DC.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is trending as investors grapple with the fund's aggressive re-pricing ahead of an accelerated lockup expiration in August. The community remains deeply divided between long-term bulls betting on Anthropic's future and skeptical bears warning of a massive disconnect between current trading prices and the fund's underlying net asset value.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML Holding is trending as investors weigh significant earnings growth against geopolitical risks following reports of U.S. scrutiny over potential, albeit denied, EUV technology exports to China. The community remains focused on the company's long-term leadership in advanced lithography and its critical role in the global AI infrastructure buildout, with many viewing pullbacks as attractive buying opportunities despite high valuations.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

MapLight Therapeutics Inc.

MapLight Therapeutics is seeing significant volatility following mixed topline results from its Phase 2 schizophrenia trial, with the community actively debating whether the decline represents a major overreaction or a fundamental warning sign. Investors are closely monitoring the stock's clinical pipeline and potential institutional selling, while others look for signs of a technical rebound amidst the heavy sell-off.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to the company's recent NSF grant and its inclusion in an IDC industry leadership assessment, fueling ongoing community debate regarding the timeline for commercial quantum utility. While bullish participants point to these milestones and government policy support as long-term catalysts, others remain skeptical, citing continued volatility and the significant valuation gap relative to current revenue.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is trending as investors weigh conflicting regulatory signals following news of a potential path for BLA resubmission, while the community remains divided over whether this represents a genuine turnaround or a high-risk gamble. Discussions are centered on upcoming ASCO data presentations and concerns regarding the company's financial runway versus the potential for political or regulatory shifts to drive approval.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
